Partnering to Enhance Mental Health
Our Partners
At the Institute for Integrative Therapies, we believe that meaningful progress in psychedelic medicine is built through strong collaboration. Our partnerships with leading pharmaceutical innovators and academic institutions help us bring rigorous, compassionate, research-driven care to the Midwest.
Clinical Research Partners
COMPASS Pathways leads the development of COMP360 psilocybin for Treatment-Resistant Depression. IIT is an approved clinical site for the COMP006 trial, contributing expertise in participant screening, dosing supervision, safety assessments, and long-term follow-up.
atai Life Sciences and Beckley Psytech are pioneering short-duration psychedelic compounds, including VLS-01 (DMT). IIT serves as a clinical trial site for the VLS-01 DMT TRD study, providing participant support, medical monitoring, and GCP-aligned research execution.
Cybin is an innovative biopharmaceutical company advancing next-generation psychedelic-derived treatments for mental health conditions. Their work focuses on precision science, improved delivery methods, and developing accessible, scalable therapeutic models.
Academic Partnerships
University of Wisconsin – Psychoactive Pharmaceutical Investigation (PPI) Master’s Program
Through this collaboration, PPI students receive hands-on training in:
-
Clinical trial operations
-
Participant screening and eligibility workflows
-
Research coordination
-
Documentation and GCP-compliant data handling
-
Observing psychedelic-adjacent care models
Advancing Psychedelic Science in the Midwest
Together, we are building a research ecosystem that supports:
-
Breakthrough drug development
-
Rigorous clinical trial execution
-
Expanded access to evidence-based psychedelic therapies
-
A thriving workforce prepared for the future of mental health care